• Je něco špatně v tomto záznamu ?

Flow-cytometric MRD detection in pediatric T-ALL: a multicenter AIEOP-BFM consensus-based guided standardized approach

M. Reiterová, S. Kohlscheen, O. Maglia, S. Sala, A. Schumich, M. Maurer-Granofszky, G. Faggin, P. Scarparo, E. Varotto, Z. Šestáková, P. Švec, T. Feuerstein, H. Vernitsky, D. Kužílková, O. Hrušák, B. Buldini, M. Dworzak, M. Brüggemann, G. Gaipa,...

. 2025 ; 63 (7) : 1419-1426. [pub] 20250313

Jazyk angličtina Země Německo

Typ dokumentu časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc25015253

OBJECTIVES: Risk-based stratification approaches using measurable residual disease (MRD) successfully help to identify T-acute lymphoblastic leukemia (T-ALL) patients at risk of relapse, whose treatment outcomes are very poor. Because of T-ALL heterogeneity and rarity, a reliable and standardized approach for flow cytometry (FC)-based MRD measurement and analysis is often missing. METHODS: Within the international AIEOP-BFM-ALL-FLOW study group we made a consensus on markers and a standard operating procedure for common 8- and 12-color T-ALL MRD panels. Custom manufactured tubes with dried backbone antibodies were tested in parallel to local FC standards. RESULTS: Altogether, 66 diagnostic and 67 day 15 samples were analyzed. We designed two guided MRD gating strategies to identify blast cells in parallel to expert-based evaluation. We proved that the optimized tubes allowed the correct identification of blast cells in all diagnostic samples. Both, expert and guided analysis of day 15 samples correlated to local standard (Spearman R=0.98 and R=0.94, respectively). Only in 2 (3 %) and 4 (6 %) patients expert gating and guided analysis results were substantially discordant from local standard, respectively. The cases that require an individualized approach may be partially identified at diagnosis through a rare immunophenotype or mixed phenotype acute leukemia status. CONCLUSIONS: Our work shows that standardized operating procedures together with guided analysis are applicable in a great majority of T-ALL cases. Further improvement of MRD detection is needed, as in some cases an individualized analytical approach is still required due to the challenging nature of the T-ALL phenotype.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25015253
003      
CZ-PrNML
005      
20250731090854.0
007      
ta
008      
250708s2025 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1515/cclm-2024-1503 $2 doi
035    __
$a (PubMed)40068909
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Reiterová, Michaela $u CLIP (Childhood Leukaemia Investigation Prague), Prague, Czech Republic $u Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University, Prague, Czech Republic $u University Hospital Motol, Prague, Czech Republic $1 https://orcid.org/0000000329645956 $7 xx0211356
245    10
$a Flow-cytometric MRD detection in pediatric T-ALL: a multicenter AIEOP-BFM consensus-based guided standardized approach / $c M. Reiterová, S. Kohlscheen, O. Maglia, S. Sala, A. Schumich, M. Maurer-Granofszky, G. Faggin, P. Scarparo, E. Varotto, Z. Šestáková, P. Švec, T. Feuerstein, H. Vernitsky, D. Kužílková, O. Hrušák, B. Buldini, M. Dworzak, M. Brüggemann, G. Gaipa, T. Kalina, AIEOP-BFM ALL Flow group
520    9_
$a OBJECTIVES: Risk-based stratification approaches using measurable residual disease (MRD) successfully help to identify T-acute lymphoblastic leukemia (T-ALL) patients at risk of relapse, whose treatment outcomes are very poor. Because of T-ALL heterogeneity and rarity, a reliable and standardized approach for flow cytometry (FC)-based MRD measurement and analysis is often missing. METHODS: Within the international AIEOP-BFM-ALL-FLOW study group we made a consensus on markers and a standard operating procedure for common 8- and 12-color T-ALL MRD panels. Custom manufactured tubes with dried backbone antibodies were tested in parallel to local FC standards. RESULTS: Altogether, 66 diagnostic and 67 day 15 samples were analyzed. We designed two guided MRD gating strategies to identify blast cells in parallel to expert-based evaluation. We proved that the optimized tubes allowed the correct identification of blast cells in all diagnostic samples. Both, expert and guided analysis of day 15 samples correlated to local standard (Spearman R=0.98 and R=0.94, respectively). Only in 2 (3 %) and 4 (6 %) patients expert gating and guided analysis results were substantially discordant from local standard, respectively. The cases that require an individualized approach may be partially identified at diagnosis through a rare immunophenotype or mixed phenotype acute leukemia status. CONCLUSIONS: Our work shows that standardized operating procedures together with guided analysis are applicable in a great majority of T-ALL cases. Further improvement of MRD detection is needed, as in some cases an individualized analytical approach is still required due to the challenging nature of the T-ALL phenotype.
650    _2
$a lidé $7 D006801
650    12
$a průtoková cytometrie $x normy $x metody $7 D005434
650    12
$a reziduální nádor $x diagnóza $7 D018365
650    _2
$a dítě $7 D002648
650    12
$a lymfoblastická leukemie-lymfom z prekurzorových T-buněk $x diagnóza $x patologie $7 D054218
650    _2
$a předškolní dítě $7 D002675
650    _2
$a konsensus $7 D032921
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a mladiství $7 D000293
650    _2
$a kojenec $7 D007223
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Kohlscheen, Saskia $u Department of Hematology, University of Schleswig-Holstein, Kiel, Germany
700    1_
$a Maglia, Oscar $u Tettamanti Center, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy
700    1_
$a Sala, Simona $u Tettamanti Center, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy
700    1_
$a Schumich, Angela $u St. Anna Children's Cancer Research Institute (CCRI), Vienna, Austria
700    1_
$a Maurer-Granofszky, Margarita $u St. Anna Children's Cancer Research Institute (CCRI), Vienna, Austria
700    1_
$a Faggin, Giovanni $u Pediatric Onco-Hematology, Stem Cell Transplant and Gene Therapy Laboratory, Istituto di Ricerca Pediatrica (IRP) - Città della Speranza, Padua, Italy $u Department of Molecular Medicine, University of Padua, Padua, Italy $1 https://orcid.org/0000000254435638
700    1_
$a Scarparo, Pamela $u Maternal and Child Health Department, Pediatric Hematology, Oncology and Stem Cell Transplant Division, University of Padua, Padua, Italy
700    1_
$a Varotto, Elena $u Pediatric Onco-Hematology, Stem Cell Transplant and Gene Therapy Laboratory, Istituto di Ricerca Pediatrica (IRP) - Città della Speranza, Padua, Italy $u Maternal and Child Health Department, Pediatric Hematology, Oncology and Stem Cell Transplant Division, University of Padua, Padua, Italy
700    1_
$a Šestáková, Zuzana $u Department of Laboratory Medicine, National Institute of Children's Diseases, Bratislava, Slovakia
700    1_
$a Švec, Peter $u Department of Pediatric Hematology and Oncology, National Institute of Children's Diseases, Bratislava, Slovakia
700    1_
$a Feuerstein, Tamar $u Schneider's Children's Medical Center, The Rina Zaizov Division of Pediatric Hematology-Oncology, Petah Tikva, Israel
700    1_
$a Vernitsky, Helly $u Sheba Medical Center, Hematology Lab, Tel Hashomer, Israel
700    1_
$a Kužílková, Daniela $u CLIP (Childhood Leukaemia Investigation Prague), Prague, Czech Republic $u Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University, Prague, Czech Republic $u University Hospital Motol, Prague, Czech Republic $1 https://orcid.org/0000000180869790
700    1_
$a Hrušák, Ondřej $u CLIP (Childhood Leukaemia Investigation Prague), Prague, Czech Republic $u Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University, Prague, Czech Republic $u University Hospital Motol, Prague, Czech Republic $1 https://orcid.org/0000000276111335 $7 xx0036691
700    1_
$a Buldini, Barbara $u Pediatric Onco-Hematology, Stem Cell Transplant and Gene Therapy Laboratory, Istituto di Ricerca Pediatrica (IRP) - Città della Speranza, Padua, Italy $u Maternal and Child Health Department, Pediatric Hematology, Oncology and Stem Cell Transplant Division, University of Padua, Padua, Italy
700    1_
$a Dworzak, Michael $u St. Anna Children's Cancer Research Institute (CCRI), Vienna, Austria $u Department of Pediatrics and Adolescent Medicine, St. Anna Children's Hospital, Medical University of Vienna, Vienna, Austria $u Labdia Labordiagnostik, Vienna, Austria
700    1_
$a Brüggemann, Monika $u Department of Hematology, University of Schleswig-Holstein, Kiel, Germany
700    1_
$a Gaipa, Giuseppe $u Tettamanti Center, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy $1 https://orcid.org/0000000210065946
700    1_
$a Kalina, Tomáš $u CLIP (Childhood Leukaemia Investigation Prague), Prague, Czech Republic $u Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University, Prague, Czech Republic $u University Hospital Motol, Prague, Czech Republic $1 https://orcid.org/0000000344752872 $7 xx0060125
710    2_
$a AIEOP-BFM ALL Flow group
773    0_
$w MED00010886 $t Clinical chemistry and laboratory medicine $x 1437-4331 $g Roč. 63, č. 7 (2025), s. 1419-1426
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40068909 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250731090849 $b ABA008
999    __
$a ok $b bmc $g 2366238 $s 1252378
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 63 $c 7 $d 1419-1426 $e 20250313 $i 1437-4331 $m Clinical chemistry and laboratory medicine $n Clin Chem Lab Med $x MED00010886
LZP    __
$a Pubmed-20250708
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace